Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma

Immune checkpoint inhibitors (ICIs), is characterized by durable responses and improved survival in non-small cell lung cancer (NSCLC). However, there is a lack of predictive biomarkers to optimize the use of ICIs in cancers. The clinical benefit of patients with lung adenocarcinoma (LUAD) harboring...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Mol Biosci
Asıl Yazarlar: Lin, Xinqing, Wang, Liqiang, Xie, Xiaohong, Qin, Yinyin, Xie, Zhanhong, Ouyang, Ming, Zhou, Chengzhi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2020
Konular:
Molecular Biosciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710974/
https://ncbi.nlm.nih.gov/pubmed/33330629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2020.602328
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller